How many clinical trials are studying Propranolol Hydrochloride?

3 recruiting trials in our tracked data involve Propranolol Hydrochloride.

What conditions is Propranolol Hydrochloride being studied for?

In our tracked recruiting trials, Propranolol Hydrochloride is being studied in trials for HIV, Healthy, Kaposi Sarcoma.

Propranolol Hydrochloride: clinical trials recruiting now

Q: Is Propranolol Hydrochloride FDA-approved?

Yes. According to the FDA drug label available through openFDA, Propranolol Hydrochloride is an FDA-approved drug. Its FDA label carries a boxed warning.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Propranolol Hydrochloride appears in the FDA drug-label database. Marketed as Propranolol Hydrochloride.
Boxed warning: The FDA label for Propranolol Hydrochloride carries a boxed warning (the FDA's most serious warning). See the full label for details.

FDA-approved use

Hypertension Propranolol Hydrochloride Extended-Release Capsules, USP, are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol Hydrochloride Extended-Release Capsules, USP, are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol Hydrochloride Extended-Release Capsules, USP, are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Migraine Propranolol Hydrochloride Extended-Release Capsules, USP, are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Hypertrophic Subaortic Stenosis Propranolol Hydrochloride Extended-Release Capsules, USP, improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.

FDA recalls / enforcement

Reason (FDA)	Classification	Status	Initiated
CGMP Deviations: Citations given to API supplier by the Italian Health Agency AIFA for several critical deficiencies which caused a recall of the API lot used to manufacture Propanolo HCl Injection. — Fresenius Kabi USA, LLC	Class II (FDA: may cause temporary or reversible harm)	Terminated	2014-08-13
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions. — CARDINAL HEALTHCARE	Class II (FDA: may cause temporary or reversible harm)	Terminated	2022-01-26

FDA label via openFDA

Phase breakdown

Early Phase 1 1 Phase 1 1 Phase 2 1

Conditions being studied

Condition	Trials
HIV	1
Healthy	1
Kaposi Sarcoma	1
Lung cancer	1
Non Small Cell Lung Cancer	1
Obesity	1
Propranolol	1
Vasodilation	1

Recruiting trials involving Propranolol Hydrochloride

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
NCT05979818 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
Propranolol for the Treatment of Kaposi Sarcoma in Adults
NCT06445166 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
NCT05219799 · Phase: Early Phase 1 · Ages: 18 Years to 45 Years · Sex: All (male and female) · 1 location

Common questions

Is Propranolol Hydrochloride FDA-approved?

Yes, marketed as Propranolol Hydrochloride. Its FDA label carries a boxed warning.

How many recruiting trials involve Propranolol Hydrochloride?

3 recruiting trials across 8 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.